Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lapatinib - Novartis

Drug Profile

Lapatinib - Novartis

Alternative Names: 572016; Cipatinib; GSK-572016; GW-2016; GW-572016; GW-572016F; Lapatinib - GlaxoSmithKline; Lapatinib ditosilate; Lapatinib ditosylate; Tykerb; Tyverb

Latest Information Update: 27 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Developer Beth Israel Deaconess Medical Center; Eddingpharm; FONDAZIONE DEL PIEMONTE PER L'ONCOLOGIA IRCC DI CANDIOLO; GlaxoSmithKline; National Taiwan University Hospital; Novartis; West German Study Group
  • Class Antineoplastics; Chlorobenzenes; Fluorobenzenes; Furans; Phenyl ethers; Quinazolines; Small molecules; Sulfones
  • Mechanism of Action Epidermal growth factor receptor antagonists; ERBB 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer
  • Phase III Brain metastases
  • Phase II/III Bladder cancer
  • Phase II Colorectal cancer; Non-small cell lung cancer
  • Discontinued Gastric cancer; Head and neck cancer; Prostate cancer

Most Recent Events

  • 31 May 2019 Sub-group adverse events analysis from a phase III trial in breast cancer presented at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO-2019)
  • 01 Jan 2019 Memorial Sloan Kettering Cancer Center and GlaxoSmithKline completes a phase II trial for Breast Cancer (Early stage disease, Combination therapy) in USA (PO) (NCT01827163)
  • 24 Aug 2018 GlaxoSmithKline completes the phase II NeoLath trial in Breast cancer (Neoadjuvant therapy, First-line therapy, Combination therapy) in Japan (PO) (UMIN000007576)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top